In a review of previous studies, McMaster University researchers observe a stronger signal for psilocybin as a treatment for obsessive-compulsive disorder than cannabinoids.
Johns Hopkins trial veteran warns venture capital threatens therapeutic integrity as psilocybin nears FDA approval ...